European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire and Lung Cancer Module (QLQ-LC13)

Name of Questionnaire

European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module (EORTC QLQ-LC13)

Description

Supplementary lung cancer-specific questionnaire to be used in conjunction with the QLQ-C30 . Both questionnaires developed and validated in patients with lung cancer ¹ . Designed for use in an international context.

Developer

EORTC Quality of Life Study Group

Address

Quality of Life Unit
EORTC Data CenterAvenue
E. Mounier 83, Bte 11B-1200
Brussels, Belgium
Tel: +32 2 774 16 06
Fax: +32 2 779 45 68

E-mail

eortc@eortc.be

URL

www.eortc.be

Cost & availability

Free for university research, fee for use in pharmaceutical company research

Administration

Self

Time to complete

under 10 minutes

Number of items

13

Domains & categories

2

Name of categories/domains

Lung cancer-related symptoms, treatment side effects

Scaling of items

1 (Not at all) to 4 (Very much)

Scoring

0 to 100. Higher scores represent increasing symptom levels.

Reliability

Validity

Symptom scale of instrument distinguished between patients with differing performance status ² .

Responsiveness

Reported, to an extent ²

Minimally important difference

Not reported

Research use

Reported – chemotherapy in advanced non-small cell lung cancer³.

With QLQ-C30: Reported – MVP chemotherapy in small cell lung cancer⁴, paclitaxel-cisplatin vs. cisplatin-teniposide in advanced non-small cell lung cancer⁵, early vs. late alternating chemotherapy in small cell lung cancer⁶, chemotherapy in advanced small cell lung cancer⁷, predictive value of initial prognostic factors in quality of life in small cell lung cancer⁸, paclitaxel and carboplatin in non-small cell lung cancer⁹, quality of life in advanced non-small cell lung cancer¹⁰, supportive care vs. supportive care plus chemotherapy in advanced non-small cell lung cancer¹¹.

Clinical use

Not reported

Languages

Danish, Dutch, English, Finnish, French, German, Greek, Hebrew, Hungarian, Italian, Japanese, Norwegian, Russian, Spanish, Swedish. Pending: Czech, Polish, Portuguese

References

1. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85:365-76.
2. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 1994; 30A:635-42.
3. Dancey J, Zee B, Osoba D, et al. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res 1997; 6:151-8.
4. Kosty MP, Fleishman SB, Herndon JE, 2nd, et al. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1994; 12:1113-20.
5. Hickish TF, Smith IE, Nicolson MC, et al. A pilot study of MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in small-cell lung cancer. Br J Cancer 1998; 77:1966-70.
6. Giaccone G, Splinter TA, Debruyne C, et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1998; 16:2133-41.
7. Joss RA, Bacchi M, Hurny C, et al. Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1995; 6:157-66.
8. Joss RA, Alberto P, Hurny C, et al. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1995; 6:41-8.
9. Bernhard J, Hurny C, Bacchi M, et al. Initial prognostic factors in small-cell lung cancer patients predicting quality of life during chemotherapy. Swiss Group for Clinical Cancer Research (SAKK). Br J Cancer 1996; 74:1660-7.
10. Kosmidis P, Mylonakis N, Fountzilas G, et al. Paclitaxel (175mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: a randomized study. Semin Oncol 1997; 24:S12-30-S12-33.
11. Herndon JE, 2nd, Fleishman S, Kosty MP, et al. A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931. Control Clin Trials 1997; 18:286-300.

Date of information

May 1999